8-K: Jaguar Health Secures $350K Debt with Warrants

Jaguar Health, Inc. announced it secured $350,000 in short-term unsecured promissory notes with 6% interest and issued warrants to purchase 350,000 common shares to accredited investors.

Summary

• Jaguar Health, Inc. (the "Company") entered into Securities Purchase Agreements with two accredited investors on January 6, 2026.
• The Company issued $350,000 in aggregate principal amount of unsecured promissory notes (the "Notes") to these investors.
• The Notes bear simple interest at a rate of six percent (6%) per annum and mature one month after issuance, on February 6, 2026.
• Any principal or interest not paid by the Maturity Date will accrue default interest at the lesser of eighteen percent (18%) per annum or the maximum amount allowed by law.
• The Company may prepay all or any portion of the Notes at any time without penalty or premium.
• As an inducement, investors received warrants (the "Warrants") to purchase up to an aggregate of 350,000 shares of the Company's common stock.
• The initial exercise price for the Warrants is $1.00 per share, subject to adjustment.
• Warrants are exercisable immediately and expire on the earlier of five years from issuance (January 6, 2031), consummation of a fundamental transaction, or a liquidation event.
• Proceeds from the financing will be used for working capital and other general corporate purposes.
• The securities were offered and sold in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act of 1933 and Rule 506 of Regulation D to accredited investors.
• This filing is an amendment to a previous 8-K filed on January 12, 2026, to correct scriveners' errors regarding the execution and closing dates of the agreements, which are now confirmed as January 6, 2026.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative. While securing financing is a positive, the short-term, high-interest nature of the unsecured debt for generic 'working capital' suggests potential liquidity pressures. The need to amend a previous filing for 'scriveners' errors also indicates administrative issues. The warrants offer future equity upside but also potential dilution.

Positives

• The Company successfully secured $350,000 in financing, providing capital for working capital and general corporate purposes.
• The Notes allow for prepayment without penalty or premium, offering flexibility to the Company.
• The Warrants provide an equity incentive for investors, potentially aligning their interests with long-term company growth.

Negatives

• The Notes have a very short maturity period of one month, which could indicate an immediate need for cash or bridge financing rather than long-term strategic funding.
• The interest rate of 6% per annum for unsecured debt, even for a short term, is relatively high, and the default interest rate of 18% is substantial.
• The use of proceeds for "working capital and other general corporate purposes" is broad and does not specify particular growth initiatives or strategic investments.
• The need to file an amendment to correct "scriveners' errors" in a previous 8-K filing suggests administrative inaccuracies in reporting.

Risks

• The Notes and Warrants have not been registered under the Securities Act of 1933, meaning they are subject to restrictions on transferability and resale.
• There is currently no public market for the Notes or the Warrants, and there is no guarantee that a public market will develop, limiting liquidity for investors.
• Warrant holders are subject to a beneficial ownership limitation of 4.99% of the outstanding common stock immediately after exercise, which may restrict their ability to fully exercise their warrants at once.
• The Company's ability to repay the Notes within one month depends on its short-term cash flow generation or securing additional financing.

Future Outlook

The Company intends to use the proceeds from this financing for working capital and other general corporate purposes. The short-term nature of the debt suggests an immediate need for liquidity, with the warrants providing a longer-term equity component for investors. The Company will need to address the repayment of the notes by February 6, 2026, either through operations or further financing.

Management Comments

• Lisa A. Conte, President and Chief Executive Officer, signed the Unsecured Promissory Note and the Securities Purchase Agreement on behalf of Jaguar Health, Inc.

Industry Context

This type of financing, involving short-term debt coupled with equity warrants, is a common method for smaller biotechnology or pharmaceutical companies like Jaguar Health to raise capital, especially when traditional debt markets may be less accessible or when seeking to minimize immediate equity dilution. The generic 'working capital' use often indicates a need to cover operational expenses or bridge funding gaps, which is typical for companies in the R&D phase or those with fluctuating revenue streams.

Comparison to Industry Standards

• The combination of unsecured promissory notes and warrants is a standard financing structure for early-stage or growth companies in the biotech sector, often used to attract investors by offering both a fixed-income return and equity upside.
• A 6% annual interest rate for unsecured debt, even for a short term, can be considered on the higher side compared to prime lending rates for established companies, but may be typical for companies with higher perceived risk or limited access to conventional credit.
• The one-month maturity period for the notes is unusually short, suggesting a very immediate and specific funding requirement, potentially for bridge financing until a larger, more structured capital event can be completed.
• The warrant exercise price of $1.00 per share, without knowing the current market price, makes it difficult to assess its attractiveness relative to industry benchmarks, but warrants are a common 'sweetener' in such deals.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if warrants are exercised, but the financing provides necessary working capital to support operations.
• Investors (Note Holders): Receive a short-term, fixed-income return with a high default interest rate, plus equity upside through warrants, but face liquidity risk due to unregistered securities.
• Employees: Continued operations supported by the new capital, potentially ensuring job security.
• Creditors: The new debt adds to the Company's liabilities, but the short maturity means it will be repaid quickly or refinanced.

Next Steps

• The Company is obligated to repay the $350,000 principal amount plus accrued interest by the Notes' Maturity Date of February 6, 2026.
• Warrant holders may exercise their warrants to purchase common stock at $1.00 per share, subject to the beneficial ownership limitation and other terms, until January 6, 2031.

Key Dates

Keywords

Jaguar Health, JAGX, Promissory Note, Unsecured Debt, Warrants, Capital Raise, Accredited Investors, SEC Filing, 8-K Amendment, Working Capital, Corporate Finance